These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38324607)

  • 1. Experiences of being treated with autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: A qualitative interview study.
    Tolf A; Gauffin H; Burman J; Landtblom AM; Flensner G
    PLoS One; 2024; 19(2):e0297573. PubMed ID: 38324607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.
    Bayas A; Berthele A; Blank N; Dreger P; Faissner S; Friese MA; Gerdes LA; Grauer OM; Häussler V; Heesen C; Janson D; Korporal-Kuhnke M; Kowarik M; Kröger N; Lünemann JD; Martin R; Meier U; Meuth S; Muraro P; Platten M; Schirmer L; Stürner KH; Stellmann JP; Scheid C; Bergh FT; Warnke C; Wildemann B; Ziemssen T
    Ther Adv Neurol Disord; 2023; 16():17562864231180730. PubMed ID: 37780055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.
    Das J; Snowden JA; Burman J; Freedman MS; Atkins H; Bowman M; Burt RK; Saccardi R; Innocenti C; Mistry S; Laud PJ; Jessop H; Sharrack B
    Mult Scler; 2021 Jul; 27(8):1198-1204. PubMed ID: 33565902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare utilization and costs associated with autologous haematopoietic stem cell transplantation in Norwegian patients with relapsing remitting multiple sclerosis.
    Gottschlich KN; Zolic-Karlsson Z; Aas E; Kvistad SAS; Bø L; Torkildsen Ø; Lehmann AK
    Mult Scler Relat Disord; 2024 Apr; 84():105507. PubMed ID: 38412758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
    Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
    Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis.
    Mariottini A; Bulgarini G; Forci B; Innocenti C; Mealli F; Mattei A; Ceccarelli C; Repice AM; Barilaro A; Mechi C; Saccardi R; Massacesi L
    Eur J Neurol; 2022 Jun; 29(6):1708-1718. PubMed ID: 35146841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
    Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
    Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
    Boffa G; Lapucci C; Sbragia E; Varaldo R; Raiola AM; Currò D; Roccatagliata L; Capello E; Laroni A; Mikulska M; Gualandi F; Uccelli A; Angelucci E; Mancardi GL; Inglese M
    Eur J Neurol; 2020 Oct; 27(10):2047-2055. PubMed ID: 32418281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "A second birthday"? Experiences of persons with multiple sclerosis treated with autologous hematopoietic stem cell transplantation-a qualitative interview study.
    Volz T; Sippel A; Fischbach F; Richter J; Willison AG; Häußler V; Heesen C
    Front Neurol; 2024; 15():1384551. PubMed ID: 38751886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haematopoietic Stem Cell Transplantation Results in Extensive Remodelling of the Clonal T Cell Repertoire in Multiple Sclerosis.
    Massey J; Jackson K; Singh M; Hughes B; Withers B; Ford C; Khoo M; Hendrawan K; Zaunders J; Charmeteau-De Muylder B; Cheynier R; Luciani F; Ma D; Moore J; Sutton I
    Front Immunol; 2022; 13():798300. PubMed ID: 35197974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation.
    Ismail A; Sharrack B; Saccardi R; Moore JJ; Snowden JA
    Curr Opin Support Palliat Care; 2019 Dec; 13(4):394-401. PubMed ID: 31599815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis.
    Chatterton S; Withers B; Sutton IJ; Milliken ST; Ma DD; Moore JJ; Massey JC
    Mult Scler; 2021 Nov; 27(13):2112-2115. PubMed ID: 33870788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis.
    Muraro PA; Martin R; Mancardi GL; Nicholas R; Sormani MP; Saccardi R
    Nat Rev Neurol; 2017 Jul; 13(7):391-405. PubMed ID: 28621766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis.
    Mariottini A; Nozzoli C; Carli I; Landi F; Gigli V; Repice AM; Ipponi A; Cecchi M; Boncompagni R; Saccardi R; Massacesi L
    Neurol Sci; 2024 Jul; 45(7):3379-3387. PubMed ID: 38277051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, the Ottawa Protocol.
    Puyade M; Brunet F; Carolina R; Fergusson N; Makedonov I; Freedman MS; Atkins H
    Curr Protoc; 2022 May; 2(5):e437. PubMed ID: 35594180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
    Muraro PA; Pasquini M; Atkins HL; Bowen JD; Farge D; Fassas A; Freedman MS; Georges GE; Gualandi F; Hamerschlak N; Havrdova E; Kimiskidis VK; Kozak T; Mancardi GL; Massacesi L; Moraes DA; Nash RA; Pavletic S; Ouyang J; Rovira M; Saiz A; Simoes B; Trnený M; Zhu L; Badoglio M; Zhong X; Sormani MP; Saccardi R;
    JAMA Neurol; 2017 Apr; 74(4):459-469. PubMed ID: 28241268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.
    Bose G; Thebault S; Rush CA; Atkins HL; Freedman MS
    Mult Scler; 2021 Feb; 27(2):167-173. PubMed ID: 32364422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Suppression of Circulating Proinflammatory Cytokines in Multiple Sclerosis Patients Following Autologous Haematopoietic Stem Cell Transplantation.
    Hendrawan K; Khoo MLM; Visweswaran M; Massey JC; Withers B; Sutton I; Ma DDF; Moore JJ
    Front Immunol; 2021; 12():782935. PubMed ID: 35126353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients' expectations of autologous hematopoietic stem cell transplantation as a treatment for MS.
    De Kleermaeker FGCM; Uitdehaag BMJ; van Oosten BW
    Mult Scler Relat Disord; 2020 Jan; 37():101467. PubMed ID: 31678857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed immunophenotyping of the hematopoietic graft from patients with multiple sclerosis undergoing autologous hematopoietic stem cell transplant.
    Massey J; Visweswaran M; Khoo M; Hendrawan K; Sutton I; Withers B; Ma D; Moore J
    Cytotherapy; 2023 Dec; 25(12):1271-1276. PubMed ID: 37737765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.